Immunoassay Market By Product (Reagents & Kits, Analyzers, Software & Services), By Technology (ELISA, Rapid Tests, Western Blotting, Radioimmunoassay, Others), By Application (Infectious Disease Testing, Oncology, Cardiology, Endocrinology, Autoimmune Disorders, Others), By End-user (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotech Companies, Academic & Research Institutes, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape the Immunoassay Market in the coming years?

The Immunoassay Market accounted for USD 27.56 Billion in 2024 and USD 28.88 Billion in 2025 is expected to reach USD 46.2 Billion by 2035, growing at a CAGR of around 4.80% between 2025 and 2035. The Immunoassay Market refers to the diagnostic test that utilizes biochemical interactions to identify and measure particular proteins, hormones, disease-causing agents, and biomarkers in the blood or other bodily fluids.

The assays play an important role in disease diagnosis, drug development, and monitoring therapy. Major trends affecting this market in the future are increasing incidences of chronic and infectious diseases, increasing personalized medicine, and the need for fast, point-of-care testing. The improved accuracy and the turnaround time are attributed to advancements in technology such as multiplex immunoassays, the lab-on-a-chip, and the integration of artificial intelligence. The future application includes extending use to oncology, autoimmune diseases, and biopharmaceuticals, particularly with the initiative to decentralize and make diagnostics at home. 

What do industry experts say about the Immunoassay Market trends?

"Immunoassays dominate clinical diagnostics due to their high throughput, automation, and cost-effectiveness. However, cross-reactivity and matrix effects remain challenges that require continuous refinement of antibody specificity and assay design."

• Dr. Eleftherios P. Diamandis, Clinical Biochemist

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Immunoassay Market?

How is rising chronic disease prevalence boosting immunoassay testing demand?

The Immunoassay Market is also immensely propelled by the increased prevalence of chronic diseases like cancer, diabetes, cardiovascular disorders, and autoimmune diseases in the world. As world populations age and their lifestyles change, the onset of these diseases has reached extremely sharp levels, especially in developed and emerging countries. An Early and proper diagnosis, and that saves time, is good, and that is precisely what Immuno-assays offer: sensitive, specific, and rapid results about the disease biomarkers. As an example, HbA1c immunoassays are considered critical in the management of diabetes, whereas PSA and CA-125 tests assist in diagnosing cancer.

To ensure quality and the automation capability that can be achieved by the product, hospitals and diagnostic labs are also integrating immunoassay-based workflows. In addition, the rise in awareness about preventative medicine has increased the practice of screening, which further boosts the rate at which tests will be conducted. Through its public health laboratories, the CDC (U.S.) performs more than 50 million immunoassay immunological diagnoses of infectious diseases annually, including HIV and hepatitis A (CDC Lab Statistics, 2023), whereas in the NHS (UK) around 30 million ELISA tests are performed per 12 months, in the number of allergies and autoimmune testing (NHS Pathology Report, 2022). These numbers highlight the huge nature of immunoassay testing in the public health systems.

Will increasing use in drug discovery accelerate market growth globally?

A boom in the area of pharmaceutical and biopharma research is seeing an augmented demand for the Immunoassay Market, particularly in drug discovery and development. The immunoassays play an important role in pharmacokinetic and toxicokinetic investigations, target validation, drug efficacy, or antibody quantification. With increasingly biologics-centric drug pipelines, the necessity to employ accurate means to detect drugs has also increased in the form of immunoassays. ELISA and other immunoassay formats play a crucial immunogenicity testing, especially of monoclonal antibodies and vaccines. These assays are also deployed to conduct high-throughput screening of pharmaceutical companies in their early-stage research.

Biomarker-based stratification and response measurement of patients are facilitated by the use of immunoassays with the increase of precision medicine and targeted therapies. The regulatory agents also need the validation of the immunoassay procedures, as the SOP in the documentation of clinical trials enhances its importance. Test volumes are also increasing on account of the global growth of contract research organizations (CROs) in the face of an increasing trend towards outsourcing. Moreover, the research investment in translational medicine and industry-academic partnerships is spurring innovation in immunoassay technologies.

Do high costs of immunoassay instruments hinder widespread market adoption?

Although it has multiple advantages, adoption by high cost of analyzers and instrumentation, particularly in resource-poor environments, serves as one of the potential barriers against the Immunoassay Market. Systems based on advanced immunoassays, such as chemiluminescence or multiplex, are either highly capital-intensive or need frequent maintenance, a barrier to smaller clinics, diagnostic laboratories, and rural hospitals. Also, the cost of reagents and consumables is relatively high, especially when it comes to high-sensitivity tests. The price of training techs and overseeing is another expense to the overall spending. In new economies, the government healthcare budgets might not be interested in such realities until the technology is subsidized or funded by international health organizations.

Due to budget limitations, smaller hospitals can postpone the adoption of immunoassays or can remain in manual or semi-automated methods. Market penetration is also hindered by the fact that areas such as parts of the Asian continent, Africa, and Latin America do not have reimbursement policies on advanced diagnostics, thus being cost-sensitive. In developed countries as well, there is a pricing pressure and competition against the manufacturers in profit margins. These are economic problems that can hamper the growth curve of the Immunoassay Market, particularly in such areas where the aspect of affordability and ability to access is top priority anyway, despite the clinical need to have some kind of precision in diagnostics.

Can home-based testing kits revolutionize access to immunoassay diagnostics?

The Immunoassay Market will be dramatically changing as the popularity of home-based test kits grows; home-based diagnostics will be as convenient and fast as they are performed outside the walls of a classical healthcare facility. With the impetus of the consumer interest in self-monitoring and the experience triggered by the COVID-19 pandemic, businesses are moving to produce more immunoassay-based quick diagnostic kits that can be used at home. These kits are able to detect pregnancy, infectious diseases, allergies, and chronic diseases, including diabetes and thyroid diseases. Improvements in miniaturization and user-friendly instruments like the lateral flow assays have enabled non-professionals to conduct tests in an accurate manner.

Increased usability and sharing of data are also facilitated by the emerging access to more and more smartphone-compatible readers and the integration of telehealth. Home diagnostics also minimise visits to the hospital, especially when these areas are remote or underrepresented regions. This decentralized approach facilitates early warning, quicker treatment choices, and improved surveillance of diseases. Regulatory agencies are already helping and enabling fast-track approvals to in-home diagnostics, further enhancing the momentum of innovation. This consumer-led transformation will work to the favor of the Immunoassay Market as accessibility, cost, and convenience of healthcare delivery become even more integral aspects of healthcare in the future.

Will AI integration improve result interpretation and reduce turnaround time?

The insertion of Artificial Intelligence (AI) and sophisticated data automation in the process of routine diagnosis has the potential to become a huge benefit to the Immunoassay Market. Artificial intelligence can improve the interpretation of complex results of immunoassays and minimise the elements of human error and subjectivity in borderline or multiplex assays. With pattern analysis of data, algorithms end up solving the challenge of making faster decisions and reporting. With the application of automation in a laboratory, AI helps to streamline the workflow of samples, control, and verification of results. Biomarker development and the overall trend of the population could also be observed with the help of predictive analytics, which is a part of public health surveillance.

The consistency of, and early detection based on, the immunoassay platforms currently under development using AI can identify anomalies or unexpected results, which permits early clinical intervention. In addition, it allows the intelligent use of reagents and machine calibration, which means less expense when in operation. The startups and the long-established players are putting money on the AI-based immunoassay systems that work within the lab information system (LIS) and electronic health record (EHR). As the realm of diagnosing gets in the direction of precision and personalized medicine, AI can augment the analytical capacity of immunoassays. The Immunoassay Market will therefore continue to trust more in digital technologies so as to enhance accuracy in diagnostics, reduce turnaround times, and offer scalable tests.

What are the key market segments in the Immunoassay industry?

Based on the Product, the Immunoassay Market has been classified into Reagents & Kits, Analyzers, Software & Services. The Reagents & Kits segment is the dominant shareholder in the Immunoassay Market as they continue to be repeatedly demanded in diagnosis procedures and research applications. They are the units necessary to carry out immunoassays using different platforms, and they are constantly used in university labs and hospitals.

This segment is further increased by the increasing usage of the test kits, which are used to detect infectious diseases, cancer biomarkers, as well as sources of chronic conditions. There are also new developments in the sensitivity and specificity of the assay, leading to reagent innovation. Reagents & kits have faster turnover and steady revenue as compared to analyzers and software, since they are fast. This segment is the leader in terms of market share, as diagnostic testing continues to spread all over the world.

Based on the Technology, the Immunoassay Market has been classified into ELISA, Rapid Tests, Western Blotting, Radioimmunoassay, and Others. ELISA (Enzyme-Linked Immunosorbent Assay) is the leading segment in the Immunoassay Market due to the fact that ELISA has gained momentum due to its high accuracy, cost-effectiveness, and wide range of applications.

ELISA is extensively applied in the identification of diseases, monitoring drugs, and the detection of biomarkers socially and scientifically. It is versatile in infectious disease, endocrinology, and oncology, which makes it a choice. In addition, it has increased its uptake in laboratories through automation and high-throughput features. Rapid tests and chemiluminescent assays are on the rise, but ELISA is still considered the pillar of immunoassay diagnostics because of its proven stability and expansion.

Which regions are leading the Immunoassay Market, and why?

North America Immunoassay Market is presently leading, due to the presence of well-developed healthcare facilities, a high level of testing performed on diagnosis, and high penetration of well-established players in the market. The U.S has a large role to play in having serious laboratory networks, huge R&D investments, and an increasing burden of chronic diseases.

The market is also boosted by the extensive use of technologically advanced immunoassay platforms, as well as a positive reimbursement policy. In addition, agencies such as the FDA have been playing the regulatory role in enabling quick innovation and authorization of products. Having the major emphasis on precision medicine and preventive diagnostics, North America is projected to take the leading role shortly.

Asia-Pacific Immunoassay Market is the fastest-growing region, due to the growing awareness of healthcare, growing disposable income, and growing diagnostics facilities. China, India, and South Korea are investing in the modernization of health care and the automation of the laboratory.

An increase in the rate of infectious diseases and the government programs to detect the disease at earlier stages are driving the use of immunoassays. The growth of domestic manufacturers and CROs is another reason why tests will be more accessible and affordable. The Asian-Pacific region promises a strong growth in the space of diagnostic immunoassay as the systems of its healthcare undergo further development.  

What does the competitive landscape of the Immunoassay Market look like?

The Immunoassay Market is competitive with a number of players worldwide and regionally competing based on innovation, product mix, pricing, and strategic partnerships. Other major market players like Abbott Laboratories, Roche RDiagnostics, Siemens Healthineers, Thermo Fisher Scientific, and Danaher Corporation currently command the market due to broad investment in R&D and distribution channels. These players are paying attention to the creation of automated and high-throughput immunoassay platforms, widening the test menu, and inculcating AI-based diagnostic tools to enhance accuracy and patient workflow. Market reach is being achieved through partnerships with hospitals, diagnostic labs, and research institutions. New firms are also joining in with their niche technologies and point-of-care testing solutions that add to the competition.

Mergers, acquisitions, and expansion into other regions are the common strategies that are being used in an effort to consolidate their market presence and reach unexploited markets. Other companies are investing in data management and remote diagnostics systems based on cloud computing to keep updated with the recent increase in decentralized healthcare. In general, it is a dynamic and innovative market in which players continuously adjust to the changing diagnostic requirements and technology.

Immunoassay Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Immunoassay industry?

• In April 2025, Labcorp announced the nationwide launch of its pTau‑217/Beta Amyloid 42 Ratio blood-based immunoassay on April 2, 2025, with 95% sensitivity and specificity comparable to PET imaging/CSF testing, marking it as the first-of-its-kind platform for Alzheimer’s diagnosis.

Report Coverage:

By Product

• Reagents & Kits
• Analyzers
• Software & Services

By Technology

• ELISA
• Rapid Tests
• Western Blotting
• Radioimmunoassay
• Others

By Application

• Infectious Disease Testing
• Oncology
• Cardiology
• Endocrinology
• Autoimmune Disorders
• Others

By End-user

• Hospitals & Clinics
• Diagnostic Laboratories
• Pharmaceutical & Biotech Companies
• Academic & Research Institutes
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Danaher Corporation
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Becton, Dickinson and Company (BD)
• bioMérieux SA
• Ortho Clinical Diagnostics
• QuidelOrtho Corporation
• PerkinElmer, Inc.
• Merck KGaA
• Sysmex Corporation
• DiaSorin S.p.A
• Agilent Technologies

Frequently Asked Questions (FAQs)